ProCE Banner Activity

CE / CME

Management of Advanced Liver Disease and Other Challenging HCV Cases

Multimedia
Led by Paul Y. Kwo, MD, a panel of experts discusses their personal approach to the management of challenging HCV patients.

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Registered Nurses : 1.00 Nursing contact {hour}

Released: June 27, 2016

Expiration: June 26, 2017

No longer available for credit.
Begin Activity

Share

Faculty

Mark S. Sulkowski

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Ira M. Jacobson

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Thomas Schiano

Thomas Schiano, MD

Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

BMS

Gilead

Janssen

Merck Human Health HIV

ViiV Healthcare

Target Audience

This activity is intended for HIV specialists, infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with HIV infection and/or chronic hepatitis C.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate the results of clinical studies of approved HCV treatments into optimized patient management strategies
  • Apply key guidelines and study data to ensure appropriate, individualized management for diverse HCV patient populations, based on HCV genotype, cirrhosis, and comorbid conditions
  • Implement practical strategies to optimize outcomes in patients receiving HCV therapy
  • Pharmacists will be better able to provide accurate and appropriate counsel as part of the treatment team
  • Nurses will be better able to provide appropriate care and counsel for patients and their families

Program Director Disclosure

Program Director

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Cocrystal, Gilead Sciences, Janssen, Merck, and Trek and funds for research support (paid to Johns Hopkins University) from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

Faculty Disclosure

Primary Author

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck; has served on speaker bureaus for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Janssen; and has received consulting fees from AbbVie, Achillion, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Trek.

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from Abbott, AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

Thomas Schiano, MD

Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Thomas Schiano, MD, has disclosed that he has received consulting fees from Alexion and funds for research support from Biotest, Gilead Sciences, Intercept, and Merck.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
1.0 contact hour may be earned for successful completion of this activity.

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity #0797-9999-16-031-H04-P. This program is designated for up to 1.0 contact hours (1.0 CEUs) of continuing pharmacy education credit.

Type of Activity
Knowledge

Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 27, 2016, through June 26, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in HIV and HCV management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.